Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Industry Consolidation Illustrated In ANDA Holder List

Executive Summary

Most of US FDA's approved ANDAs are owned by a handful of firms, while the vast majority of owners have between one and five.

You may also be interested in...

ANDA Holder Fee Will Start With Industry-Driven Database 'Clean-Up'

FDA is again relying on sponsor self-reporting as it launches GDUFA II.

Generic Drug User Fees Will Jump More Than 50% In FY 2018

GDUFA II's fee structure shifts burden from manufacturers to sponsors though 'ANDA holder fee.'

GDUFA II: ANDAs, Not Facilities Will Govern Revenue

Since applications comprise most of the workload, they will be the focus in the next generic drug user fee cycle.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts